{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:04:27Z","timestamp":1786982667354,"version":"build-2736575974"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:00:00Z","timestamp":1707523200000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s13555-024-01099-y","type":"journal-article","created":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T07:02:13Z","timestamp":1707548533000},"page":"323-339","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9851-088X","authenticated-orcid":false,"given":"Joshua","family":"Burshtein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milaan","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Zakria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Lockshin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Crowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Shahriari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil J.","family":"Korman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Chovatiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Kalb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,10]]},"reference":[{"issue":"11","key":"1099_CR1","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.3390\/ijms18112427","volume":"18","author":"P Gisondi","year":"2017","unstructured":"Gisondi P, Del Giglio M, Girolomoni G. Treatment approaches to moderate to severe psoriasis. Int J Mol Sci. 2017;18(11):2427. https:\/\/doi.org\/10.3390\/ijms18112427.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"1099_CR2","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2165\/00128071-200506060-00005","volume":"6","author":"AB Kimball","year":"2005","unstructured":"Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005;6(6):383\u201392. https:\/\/doi.org\/10.2165\/00128071-200506060-00005.","journal-title":"Am J Clin Dermatol"},{"issue":"11","key":"1099_CR3","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.2165\/11591580-000000000-00000","volume":"30","author":"G Raho","year":"2012","unstructured":"Raho G, Koleva DM, Garattini L, Naldi L. The burden of moderate to severe psoriasis: an overview. Pharmacoeconomics. 2012;30(11):1005\u201313. https:\/\/doi.org\/10.2165\/11591580-000000000-00000.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"1099_CR4","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.jaad.2020.11.039","volume":"84","author":"J Burshtein","year":"2021","unstructured":"Burshtein J, Strunk A, Garg A. Incidence of psoriasis among adults in the United States: a sex- and age-adjusted population analysis. J Am Acad Dermatol. 2021;84(4):1023\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2020.11.039.","journal-title":"J Am Acad Dermatol"},{"key":"1099_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011535.pub2","author":"E Sbidian","year":"2017","unstructured":"Sbidian E, Chaimani A, Garcia-Doval I, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2017. https:\/\/doi.org\/10.1002\/14651858.CD011535.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"1099_CR6","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.3389\/fimmu.2018.01682","volume":"9","author":"NC Brembilla","year":"2018","unstructured":"Brembilla NC, Senra L, Boehncke WH. The IL-17 family of cytokines in psoriasis: IL-17A and beyond. Front Immunol. 2018;9:1682. https:\/\/doi.org\/10.3389\/fimmu.2018.01682.","journal-title":"Front Immunol"},{"issue":"4","key":"1099_CR7","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1208\/s12248-017-0094-4","volume":"19","author":"C Soderstrom","year":"2017","unstructured":"Soderstrom C, Berstein G, Zhang W, et al. Ultra-sensitive measurement of IL-17A and IL-17F in psoriasis patient serum and skin. AAPS J. 2017;19(4):1218\u201322. https:\/\/doi.org\/10.1208\/s12248-017-0094-4.","journal-title":"AAPS J"},{"issue":"1","key":"1099_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s13555-017-0211-4","volume":"8","author":"D Pariser","year":"2018","unstructured":"Pariser D, Frankel E, Schlessinger J, et al. Efficacy of secukinumab in the treatment of moderate to severe plaque psoriasis in the North American subgroup of patients: pooled analysis of four phase\u00a03 studies. Dermatol Ther. 2018;8(1):17\u201332. https:\/\/doi.org\/10.1007\/s13555-017-0211-4.","journal-title":"Dermatol Ther"},{"issue":"1","key":"1099_CR9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","volume":"79","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Smolen JS, Behrens F, et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 2020;79(1):123\u201331. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215386.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1099_CR10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s13555-016-0121-x","volume":"6","author":"B Farahnik","year":"2016","unstructured":"Farahnik B, Beroukhim K, Abrouk M, et al. Brodalumab for the treatment of psoriasis: a review of phase\u00a0III trials. Dermatol Ther. 2016;6(2):111\u201324. https:\/\/doi.org\/10.1007\/s13555-016-0121-x.","journal-title":"Dermatol Ther"},{"issue":"4","key":"1099_CR11","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s40259-019-00361-6","volume":"33","author":"J Reis","year":"2019","unstructured":"Reis J, Vender R, Torres T. Bimekizumab: the first dual inhibitor of interleukin (IL)-17A and IL-17F for the treatment of psoriatic disease and ankylosing spondylitis. BioDrugs. 2019;33(4):391\u20139. https:\/\/doi.org\/10.1007\/s40259-019-00361-6.","journal-title":"BioDrugs"},{"issue":"5","key":"1099_CR12","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1111\/bcp.13185","volume":"83","author":"S Glatt","year":"2017","unstructured":"Glatt S, Helmer E, Haier B, et al. First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis. Br J Clin Pharmacol. 2017;83(5):991\u20131001. https:\/\/doi.org\/10.1111\/bcp.13185.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"1099_CR13","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.jaad.2020.05.105","volume":"83","author":"A Blauvelt","year":"2020","unstructured":"Blauvelt A, Papp KA, Merola JF, et al. Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase\u00a02b extension study. J Am Acad Dermatol. 2020;83(5):1367\u201374. https:\/\/doi.org\/10.1016\/j.jaad.2020.05.105.","journal-title":"J Am Acad Dermatol"},{"issue":"10273","key":"1099_CR14","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","volume":"397","author":"KB Gordon","year":"2021","unstructured":"Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase\u00a03 trial. Lancet. 2021;397(10273):475\u201386. https:\/\/doi.org\/10.1016\/S0140-6736(21)00126-4.","journal-title":"Lancet"},{"issue":"4","key":"1099_CR15","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/bjd.20827","volume":"186","author":"R Oliver","year":"2022","unstructured":"Oliver R, Krueger JG, Glatt S, et al. Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase\u00a0IIa, randomized, double-blind multicentre study. Br J Dermatol. 2022;186(4):652\u201363. https:\/\/doi.org\/10.1111\/bjd.20827.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1099_CR16","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1093\/bjd\/ljac089","volume":"188","author":"G Kokolakis","year":"2023","unstructured":"Kokolakis G, Warren RB, Strober B, et al. Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase\u00a0III\/IIIb trials. Br J Dermatol. 2023;188(3):330\u201340. https:\/\/doi.org\/10.1093\/bjd\/ljac089.","journal-title":"Br J Dermatol"},{"issue":"10370","key":"1099_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0140-6736(22)02302-9","volume":"401","author":"IB McInnes","year":"2023","unstructured":"McInnes IB, Asahina A, Coates LC, et al. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase\u00a03 trial (BE OPTIMAL). Lancet. 2023;401(10370):25\u201337. https:\/\/doi.org\/10.1016\/S0140-6736(22)02302-9.","journal-title":"Lancet"},{"issue":"10370","key":"1099_CR18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","volume":"401","author":"JF Merola","year":"2023","unstructured":"Merola JF, Landew\u00e9 R, McInnes IB, et al. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-\u03b1 inhibitors: a randomised, double-blind, placebo-controlled, phase\u00a03 trial (BE COMPLETE). Lancet. 2023;401(10370):38\u201348. https:\/\/doi.org\/10.1016\/S0140-6736(22)02303-0.","journal-title":"Lancet"},{"issue":"10222","key":"1099_CR19","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S0140-6736(19)33161-7","volume":"395","author":"CT Ritchlin","year":"2020","unstructured":"Ritchlin CT, Kavanaugh A, Merola JF, et al. Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase\u00a02b trial. Lancet. 2020;395(10222):427\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(19)33161-7.","journal-title":"Lancet"},{"issue":"2","key":"1099_CR20","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jaad.2018.03.037","volume":"79","author":"KA Papp","year":"2018","unstructured":"Papp KA, Merola JF, Gottlieb AB, et al. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase\u00a02b trial. J Am Acad Dermatol. 2018;79(2):277-286.e10. https:\/\/doi.org\/10.1016\/j.jaad.2018.03.037.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1099_CR21","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jaad.2023.04.063","volume":"89","author":"B Strober","year":"2023","unstructured":"Strober B, Paul C, Blauvelt A, et al. Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: two-year interim results from the open-label extension of the randomized BE RADIANT phase\u00a03b trial. J Am Acad Dermatol. 2023;89(3):486\u201395. https:\/\/doi.org\/10.1016\/j.jaad.2023.04.063.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"1099_CR22","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1001\/jamadermatol.2022.1185","volume":"158","author":"KB Gordon","year":"2022","unstructured":"Gordon KB, Langley RG, Warren RB, et al. Bimekizumab safety in patients with moderate to severe plaque psoriasis: pooled results from phase\u00a02 and phase\u00a03 randomized clinical trials. JAMA Dermatol. 2022;158(7):735. https:\/\/doi.org\/10.1001\/jamadermatol.2022.1185.","journal-title":"JAMA Dermatol"},{"key":"1099_CR23","doi-asserted-by":"publisher","first-page":"1243843","DOI":"10.3389\/fmed.2023.1243843","volume":"10","author":"L Gargiulo","year":"2023","unstructured":"Gargiulo L, Narcisi A, Ibba L, et al. Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis). Front Med (Lausanne). 2023;10:1243843. https:\/\/doi.org\/10.3389\/fmed.2023.1243843.","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"1099_CR24","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/jocd.15543","volume":"22","author":"M Megna","year":"2023","unstructured":"Megna M, Battista T, Potestio L, et al. A case of erythrodermic psoriasis rapidly and successfully treated with bimekizumab. J Cosmet Dermatol. 2023;22(3):1146\u20138. https:\/\/doi.org\/10.1111\/jocd.15543.","journal-title":"J Cosmet Dermatol"},{"issue":"11","key":"1099_CR25","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1038\/jid.2015.208","volume":"135","author":"RB Warren","year":"2015","unstructured":"Warren RB, Smith CH, Yiu ZZN, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2015;135(11):2632\u201340. https:\/\/doi.org\/10.1038\/jid.2015.208.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"1099_CR26","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3122\/jabfm.17.1.59","volume":"17","author":"MH Ebell","year":"2004","unstructured":"Ebell MH, Siwek J, Weiss BD, et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. J Am Board Fam Med. 2004;17(1):59\u201367. https:\/\/doi.org\/10.3122\/jabfm.17.1.59.","journal-title":"J Am Board Fam Med"},{"key":"1099_CR27","doi-asserted-by":"publisher","unstructured":"Hsu C-C, Sandford BA. The Delphi technique: making sense of consensus. In: Practical assessment, research, and evaluation, vol. 12, Article 10. 2019. https:\/\/doi.org\/10.7275\/pdz9-th90.","DOI":"10.7275\/pdz9-th90"},{"issue":"5","key":"1099_CR28","doi-asserted-by":"publisher","first-page":"291","DOI":"10.25251\/skin.3.5.1","volume":"3","author":"B Berman","year":"2019","unstructured":"Berman B, Ceilley R, Cockerell C, et al. Appropriate use criteria for the integration of diagnostic and prognostic gene expression profile assays into the management of cutaneous malignant melanoma: an expert panel consensus-based modified delphi process assessment. SKIN J Cutan Med. 2019;3(5):291\u2013306. https:\/\/doi.org\/10.25251\/skin.3.5.1.","journal-title":"SKIN J Cutan Med"},{"issue":"2","key":"1099_CR29","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jaad.2017.09.078","volume":"78","author":"DM Thiboutot","year":"2018","unstructured":"Thiboutot DM, Dr\u00e9no B, Abanmi A, et al. Practical management of acne for clinicians: an international consensus from the global alliance to improve outcomes in acne. J Am Acad Dermatol. 2018;78(2):S1\u201323. https:\/\/doi.org\/10.1016\/j.jaad.2017.09.078.","journal-title":"J Am Acad Dermatol"},{"key":"1099_CR30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/jdv.12560","volume":"28","author":"MA Richard","year":"2014","unstructured":"Richard MA, Barnetche T, Rouzaud M, et al. Evidence-based recommendations on the role of dermatologists in the diagnosis and management of psoriatic arthritis: systematic review and expert opinion. J Eur Acad Dermatol Venereol. 2014;28:3\u201312. https:\/\/doi.org\/10.1111\/jdv.12560.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1099_CR31","doi-asserted-by":"publisher","first-page":"556","DOI":"10.25251\/skin.7.1.1","volume":"7","author":"D Zakria","year":"2023","unstructured":"Zakria D, Brownstone N, Berman B, et al. Incorporating prognostic gene expression profile assays into the management of cutaneous melanoma: an expert consensus panel. SKIN J Cutan Med. 2023;7(1):556\u201369. https:\/\/doi.org\/10.25251\/skin.7.1.1.","journal-title":"SKIN J Cutan Med"},{"issue":"5","key":"1099_CR32","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/1346-8138.14834","volume":"46","author":"B Bayaraa","year":"2019","unstructured":"Bayaraa B, Imafuku S. Sustainability and switching of biologics for psoriasis and psoriatic arthritis at Fukuoka University Psoriasis Registry. J Dermatol. 2019;46(5):389\u201398. https:\/\/doi.org\/10.1111\/1346-8138.14834.","journal-title":"J Dermatol"},{"issue":"1","key":"1099_CR33","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000504839","volume":"237","author":"E \u00d6zkur","year":"2021","unstructured":"\u00d6zkur E, K\u0131van\u00e7 Altunay \u0130, O\u011fuz Topal \u0130, et al. Switching biologics in the treatment of psoriasis: a multicenter experience. Dermatology. 2021;237(1):22\u201330. https:\/\/doi.org\/10.1159\/000504839.","journal-title":"Dermatology"},{"issue":"8","key":"1099_CR34","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1007\/s13555-022-00760-8","volume":"12","author":"A Armstrong","year":"2022","unstructured":"Armstrong A, Fahrbach K, Leonardi C, et al. Efficacy of bimekizumab and other biologics in moderate to severe plaque psoriasis: a systematic literature review and a network meta-analysis. Dermatol Ther. 2022;12(8):1777\u201392. https:\/\/doi.org\/10.1007\/s13555-022-00760-8.","journal-title":"Dermatol Ther"},{"issue":"1","key":"1099_CR35","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00296-018-4195-x","volume":"39","author":"A Gottlieb","year":"2019","unstructured":"Gottlieb A, Gratacos J, Dikranian A, et al. Treatment patterns, unmet need, and impact on patient-reported outcomes of psoriatic arthritis in the United States and Europe. Rheumatol Int. 2019;39(1):121\u201330. https:\/\/doi.org\/10.1007\/s00296-018-4195-x.","journal-title":"Rheumatol Int"},{"issue":"4","key":"1099_CR36","doi-asserted-by":"publisher","first-page":"431","DOI":"10.3899\/jrheum.160973","volume":"44","author":"B Michelsen","year":"2017","unstructured":"Michelsen B, Diamantopoulos AP, H\u00f8iberg HK, Soldal DM, Kavanaugh A, Haugeberg G. Need for improvement in current treatment of psoriatic arthritis: study of an outpatient clinic population. J Rheumatol. 2017;44(4):431\u20136. https:\/\/doi.org\/10.3899\/jrheum.160973.","journal-title":"J Rheumatol"},{"issue":"5","key":"1099_CR37","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.3390\/ijms21051690","volume":"21","author":"M Kamata","year":"2020","unstructured":"Kamata M, Tada Y. Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review. Int J Mol Sci. 2020;21(5):1690. https:\/\/doi.org\/10.3390\/ijms21051690.","journal-title":"Int J Mol Sci"},{"key":"1099_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.03.035","author":"S Cole","year":"2023","unstructured":"Cole S, Manghera A, Burns L, et al. Differential regulation of IL-17A and IL-17F via STAT5 contributes to psoriatic disease. J Allergy Clin Immunol. 2023. https:\/\/doi.org\/10.1016\/j.jaci.2023.03.035.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"1099_CR39","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa2102383","volume":"385","author":"K Reich","year":"2021","unstructured":"Reich K, Warren RB, Lebwohl M, et al. Bimekizumab versus secukinumab in plaque psoriasis. N Engl J Med. 2021;385(2):142\u201352. https:\/\/doi.org\/10.1056\/NEJMoa2102383.","journal-title":"N Engl J Med"},{"issue":"2","key":"1099_CR40","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa2102388","volume":"385","author":"RB Warren","year":"2021","unstructured":"Warren RB, Blauvelt A, Bagel J, et al. Bimekizumab versus adalimumab in plaque psoriasis. N Engl J Med. 2021;385(2):130\u201341. https:\/\/doi.org\/10.1056\/NEJMoa2102388.","journal-title":"N Engl J Med"},{"issue":"10273","key":"1099_CR41","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","volume":"397","author":"K Reich","year":"2021","unstructured":"Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase\u00a03 trial. Lancet. 2021;397(10273):487\u201398. https:\/\/doi.org\/10.1016\/S0140-6736(21)00125-2.","journal-title":"Lancet"},{"issue":"4","key":"1099_CR42","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","volume":"371","author":"RG Langley","year":"2014","unstructured":"Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis \u2014 results of two phase\u00a03 trials. N Engl J Med. 2014;371(4):326\u201338. https:\/\/doi.org\/10.1056\/NEJMoa1314258.","journal-title":"N Engl J Med"},{"issue":"5","key":"1099_CR43","doi-asserted-by":"publisher","first-page":"321","DOI":"10.2165\/11587890-000000000-00000","volume":"12","author":"C Leonardi","year":"2011","unstructured":"Leonardi C, Papp K, Strober B, et al. The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials. Am J Clin Dermatol. 2011;12(5):321\u201337. https:\/\/doi.org\/10.2165\/11587890-000000000-00000.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"1099_CR44","first-page":"160","volume":"11","author":"D Zaghi","year":"2012","unstructured":"Zaghi D, Krueger GG, Callis DK. Ustekinumab: a review in the treatment of plaque psoriasis and psoriatic arthritis. J Drugs Dermatol JDD. 2012;11(2):160\u20137.","journal-title":"J Drugs Dermatol JDD"},{"issue":"6","key":"1099_CR45","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1093\/bjd\/ljad035","volume":"188","author":"B Strober","year":"2023","unstructured":"Strober B, Tada Y, Mrowietz U, et al. Bimekizumab maintenance of response through 3\u00a0years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial. Br J Dermatol. 2023;188(6):749\u201359. https:\/\/doi.org\/10.1093\/bjd\/ljad035.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1099_CR46","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1093\/bjd\/ljac021","volume":"188","author":"D Tha\u00e7i","year":"2023","unstructured":"Tha\u00e7i D, Vender R, De Rie MA, et al. Safety and efficacy of bimekizumab through 2\u00a0years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial. Br J Dermatol. 2023;188(1):22\u201331. https:\/\/doi.org\/10.1093\/bjd\/ljac021.","journal-title":"Br J Dermatol"},{"key":"1099_CR47","doi-asserted-by":"publisher","DOI":"10.23736\/S2784-8671.20.06580-3","author":"C Rodr\u00edguez-Cerdeira","year":"2021","unstructured":"Rodr\u00edguez-Cerdeira C, Gonz\u00e1lez-Cesp\u00f3n JL, Mart\u00ednez-Herrera E, et al. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Ital J Dermatol Venereol. 2021. https:\/\/doi.org\/10.23736\/S2784-8671.20.06580-3.","journal-title":"Ital J Dermatol Venereol"},{"issue":"4","key":"1099_CR48","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s40257-016-0206-4","volume":"17","author":"AW Armstrong","year":"2016","unstructured":"Armstrong AW, Bukhalo M, Blauvelt A. A clinician\u2019s guide to the diagnosis and treatment of candidiasis in patients with psoriasis. Am J Clin Dermatol. 2016;17(4):329\u201336. https:\/\/doi.org\/10.1007\/s40257-016-0206-4.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"1099_CR49","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s13555-022-00687-0","volume":"12","author":"AW Armstrong","year":"2022","unstructured":"Armstrong AW, Blauvelt A, Mrowietz U, et al. A practical guide to the management of oral candidiasis in patients with plaque psoriasis receiving treatments that target interleukin-17. Dermatol Ther. 2022;12(3):787\u2013800. https:\/\/doi.org\/10.1007\/s13555-022-00687-0.","journal-title":"Dermatol Ther"},{"issue":"11","key":"1099_CR50","doi-asserted-by":"publisher","first-page":"6479","DOI":"10.1007\/s00784-022-04716-2","volume":"26","author":"SQS Kessler","year":"2022","unstructured":"Kessler SQS, Lang PM, Dal-Pizzol TS, Montagner F. Resistance profiles to antifungal agents in Candida albicans isolated from human oral cavities: systematic review and meta-analysis. Clin Oral Investig. 2022;26(11):6479\u201389. https:\/\/doi.org\/10.1007\/s00784-022-04716-2.","journal-title":"Clin Oral Investig"},{"key":"1099_CR51","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223595","author":"D Van Der Heijde","year":"2023","unstructured":"Van Der Heijde D, Deodhar A, Baraliakos X, et al. Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase\u00a03 randomised controlled trials. Ann Rheum Dis. 2023. https:\/\/doi.org\/10.1136\/ard-2022-223595.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1099_CR52","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1001\/jamadermatol.2018.3631","volume":"154","author":"Y Fu","year":"2018","unstructured":"Fu Y, Lee CH, Chi CC. Association of psoriasis with inflammatory bowel disease: a systematic review and meta-analysis. JAMA Dermatol. 2018;154(12):1417. https:\/\/doi.org\/10.1001\/jamadermatol.2018.3631.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1099_CR53","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/joim.13282","volume":"290","author":"CRH Hedin","year":"2021","unstructured":"Hedin CRH, Sonkoly E, Eberhardson M, St\u00e5hle M. Inflammatory bowel disease and psoriasis: modernizing the multidisciplinary approach. J Intern Med. 2021;290(2):257\u201378. https:\/\/doi.org\/10.1111\/joim.13282.","journal-title":"J Intern Med"},{"issue":"12","key":"1099_CR54","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","volume":"61","author":"W Hueber","year":"2012","unstructured":"Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61(12):1693\u2013700. https:\/\/doi.org\/10.1136\/gutjnl-2011-301668.","journal-title":"Gut"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01099-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01099-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01099-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T13:22:15Z","timestamp":1708694535000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01099-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["1099"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01099-y","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"6 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Benjamin Lockshin has served as an advisor, speaker, and\/or investigator for Abbvie, Novartis, Eli Lilly, Sanofi, Regerneron, Incyte, Leo, UCB, Strata Skin Sciences, Arcutis, Dermavant, BMS, Dermtech, and as a consultant for Abbvie, Novartis, Eli Lilly, DermTech, Strata Skin Sciences, CorEvitas Registry, Leo, UCB, Boehringer Ingelheim, Dermavant, BMS, Regeneron, Sanofi. Investigator for Abbvie, Novartis, Eli Lilly, Sanofi, Regerneron, Leo, Pfizer, Franklin Bioscience, Trevi Therapeutics, Inc., Vanda, Celgene, Strata Skin Sciences, Galderma, Amgen, Dermira, and Castle. Jeff Crowley has served as consultant, speaker, and investigator for Abbvie, Lilly, Janssen, Regeneron, Sanofi, UCB, Boerhinger Ingelheim, Bristol Myers Squibb, and Arcutis. Joseph F. Merola is a consultant and\/or investigator for Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Abbvie, Dermavant, Eli Lilly, Incyte, Novartis, Janssen, UCB, Sanofi-Regeneron, Sun Pharma, Biogen, Pfizer and Leo Pharma. Ken Gordon has received honoraria and\/or research support from AbbVie, Amgen, BMS, Boehringer Ingelheim, Dermavant, Dice, Eli Lilly, Incyte, Janssen, Novartis, MoonLake, Pfizer, Protagonist, UCB, Union. Mona Shahriari has served as an advisor, consultant, speaker, and\/or investigator for AbbVie, Arcutis, Bristol Myers Squibb, Dermavant, Janssen, Leo Pharma, Lilly USA, Novartis, Ortho Dermatologics, Sanofi-Genzyme, Regeneron, UCB, Pfizer, CorEvitas Psoriasis Registry, Dermira, Cara, Union, and Mindera. Neil J. Korman has served as an advisor, consultant, speaker, or investigator for: AbbVie, Abcentra, Amgen, Argenx, Astrazeneca, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Castle Bioscience, Celgene, Chemocentryx, Dermavant, Eli Lilly, Galderma, Incyte, Janssen, Kyowa Hakko Kirin Pharma, Leo Pharma, Menlo Therapeutics, Novartis, Olix, Pfizer, Principia, Regeneron, Sun Pharma, Trevi, UCB, XBiotech. Raj Chovatiya has served as an advisor, consultant, speaker, and\/or investigator for AbbVie, Apogee Therapeutics, Arcutis, Argenx, ASLAN Pharmaceuticals, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Dermavant, Eli Lilly and Company, FIDE, Galderma, Genentech, GSK, Incyte, Janssen, LEO Pharma, L\u2019Or\u00e9al, Nektar Therapeutics, Opsidio, Pfizer Inc., Regeneron, RAPT, Sanofi, and UCB. Robert Kalb has received research funding from AbbVie, Amgen, CorEvitas LLC, Janssen Ortho Inc, UCB and the University of Pennsylvania. He has been on the data safety monitoring board for studies with Eli Lilly and the pharmaceutical product development group. He has been a consult for Janssen Ortho and UCB. These grants are paid to his institution. Mark Lebwohl is an employee of Mount Sinai and receives research funds from: Abbvie, Amgen, Arcutis, Avotres, Boehringer Ingelheim, Cara therapeutics, Dermavant Sciences, Eli Lilly, Incyte, Inozyme, Janssen Research & Development, LLC, Ortho Dermatologics, Pfizer, Sanofi-Regeneron, and UCB, Inc., and is a consultant for Almirall, AltruBio Inc., AnaptysBio, Apogee, Arcutis, Inc., AstraZeneca, Atomwise, Avotres Therapeutics, Brickell Biotech, Boehringer-Ingelheim, Bristol-Myers Squibb, Castle Biosciences, Celltrion, Corevitas, Dermavant Sciences, EPI, Evommune, Inc., Facilitation of International Dermatology Education,Forte biosciences, Foundation for Research and Education in Dermatology, Galderma, Genentech, Incyte, LEO Pharma, Meiji Seika Pharma, Mindera, Pfizer, Sanofi-Regeneron, Seanergy, Strata, Takeda, Trevi, and Verrica. Joshua Burshtein, Milaan Shah and Danny Zakria have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All panel experts involved in the study are authors of the manuscript and were informed of the study\u2019s objectives. All of the experts support the submission of this manuscript to a peer-reviewed journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}